Vaxxinity Inc banner

Vaxxinity Inc
OTC:VAXX

Watchlist Manager
Vaxxinity Inc Logo
Vaxxinity Inc
OTC:VAXX
Watchlist
Price: 0.01 USD 9 900% Market Closed
Market Cap: $1.3m

Vaxxinity Inc
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Vaxxinity Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Vaxxinity Inc
OTC:VAXX
Stock-Based Compensation
$7.5m
CAGR 3-Years
95%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$955m
CAGR 3-Years
12%
CAGR 5-Years
5%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
$894m
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
$494m
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$685.9m
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
11%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
$993.7m
CAGR 3-Years
11%
CAGR 5-Years
18%
CAGR 10-Years
8%
No Stocks Found

Vaxxinity Inc
Glance View

Market Cap
1.3m USD
Industry
Biotechnology

Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas and currently employs 89 full-time employees. The company went IPO on 2021-11-11. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) enables a new class of therapeutics that will improve the access to treatments for a range of indications. Its Vaxxine Platform is designed to connect the immune system to convert the body into its own drug factory, stimulating the production of antibodies with a therapeutic or protective effect. Its technology uses synthetic peptides to mimic and optimally combine biological epitopes in order to selectively activate the immune system, producing antibodies against only the desired targets, including self-antigens, making possible the safe and effective treatment of chronic diseases by vaccines. The modular and synthetic nature of its Vaxxine Platform provides significant in candidate development and has generated multiple product candidates that it is designing for many chronic diseases.

VAXX Intrinsic Value
Not Available

See Also

What is Vaxxinity Inc's Stock-Based Compensation?
Stock-Based Compensation
7.5m USD

Based on the financial report for Dec 31, 2023, Vaxxinity Inc's Stock-Based Compensation amounts to 7.5m USD.

What is Vaxxinity Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
95%

Over the last year, the Stock-Based Compensation growth was -14%. The average annual Stock-Based Compensation growth rates for Vaxxinity Inc have been 95% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett